Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features

Psychiatry Research

Volumn 198, Issue 2, 2012, Pages 212-215

  Garcia Rizo, Clemente ^a   Fernandez Egea, Emilio ^b,c   Oliveira, Cristina ^a   Justicia, Azucena ^b   Bernardo, Miguel ^a,d,e   Kirkpatrick, Brian ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^f TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

C reactive protein; Deficit schizophrenia; First episode psychosis; Glucose tolerance; Interleukin 6; Negative symptoms

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HYDROCORTISONE; INTERLEUKIN 6;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RISK FACTOR;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS;

EID: 84868159779     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.08.014     Document Type: Article

References (51)

1. Addington J., Saeedi H., Addington D. The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome. Schizophrenia Research 2005, 78:35-43.
2. Akanji A.O., Ohaeri J.U., Al-Shammri S., Fatania H.R. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Research 2009, 169:56-61.
3. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 2007, 90:179-185.
4. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophrenia Research 1999, 37:97-106.
5. Arango C., Bobes J., Kirkpatrick B., Garcia-Garcia M., Rejas J. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. European Neuropsychopharmacology 2011, 21(12):867-875. doi:10.1016/j.euroneuro.2011.03.005.
6. Bresee C.J., Delrahim K., Maddux R.E., Dolnak D., Ahmadpour O., Rapaport M.H. The effects of celecoxib augmentation on cytokine levels in schizophrenia. International Journal of Neuropsychopharmacology 2006, 9:343-348.
7. Carrizo E., Fernandez V., Quintero J., Connell L., Rodriguez Z., Mosquera M., Acosta A., Baptista T. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Research 2008, 103:83-93.
8. Chemerinski E., Reichenberg A., Kirkpatrick B., Bowie C.R., Harvey P.D. Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status. Schizophrenia Research 2006, 85:12-19.
9. Corcoran C., Walker E., Huot R., Mittal V., Tessner K., Kestler L., Malaspina D. The stress cascade and schizophrenia: etiology and onset. Schizophrenia Bulletin 2003, 29:671-692.
10. Deverman B.E., Patterson P.H. Cytokines and CNS development. Neuron 2009, 64:61-78.
11. Dickerson F., Kirkpatrick B., Boronow J., Stallings C., Origoni A., Yolken R. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophrenia Bulletin 2006, 32:396-400.
12. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophrenia Research 2007, 93:261-265.
13. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Research 2007, 149:267-271.
14. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. British Journal of Psychiatry 2009, 194:434-438.
15. Ganguli R., Yang Z., Shurin G., Chengappa K.N., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Research 1994, 51:1-10.
16. Hollinshead A.B., Redlich S. Social Class and Mental Illness 1958, John Wiley, New York.
17. Kirkpatrick B., Galderisi S. Deficit schizophrenia: an update. World Psychiatry 2008, 7:143-147.
18. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Research 1989, 30:119-123.
19. Kirkpatrick B., Buchanan R.W., Breier A., Carpenter W.T. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Research 1993, 47:47-56.
20. Kirkpatrick B., Buchanan R.W., Breier A., Carpenter W.T. Depressive symptoms and the deficit syndrome of schizophrenia. Journal of Nervous and Mental Disease 1994, 182:452-455.
21. Kirkpatrick B., Amador X.F., Flaum M., Yale S.A., Gorman J.M., Carpenter W.T., Tohen M., McGlashan T. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophrenia Research 1996, 20:69-77.
22. Kirkpatrick B., Amador X.F., Yale S.A., Bustillo J.R., Buchanan R.W., Tohen M. The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs. Schizophrenia Research 1996, 20:79-90.
23. Kirkpatrick B., Ram R., Bromet E. The deficit syndrome in the Suffolk County Mental Health Project. Schizophrenia Research 1996, 22:119-126.
24. Kirkpatrick B., Ram R., Amador X.F., Buchanan R.W., McGlashan T., Tohen M., Bromet E. Summer birth and the deficit syndrome of schizophrenia. American Journal of Psychiatry 1998, 155:1221-1226.
25. Kirkpatrick B., Ross D.E., Walsh D., Karkowski L., Kendler K.S. Family characteristics of deficit and nondeficit schizophrenia in the Roscommon Family Study. Schizophrenia Research 2000, 45:57-64.
26. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Archives of General Psychiatry 2001, 58:165-171.
27. Kirkpatrick B., Herrera Castanedo S., Vazquez-Barquero J.L. Summer birth and deficit schizophrenia: Cantabria, Spain. Journal of Nervous and Mental Disease 2002, 190:526-532.
28. Kirkpatrick B., Tek C., Allardyce J., Morrison G., McCreadie R.G. Summer birth and deficit schizophrenia in Dumfries and Galloway, southwestern Scotland. American Journal of Psychiatry 2002, 159:1382-1387.
29. Kirkpatrick B., Messias E.M., Tek C. Substance abuse and the heterogeneity of schizophrenia a population-based study. Schizophrenia Research 2003, 62:293-294.
30. Kirkpatrick B., Messias E., LaPorte D. Schizoid-like features and season of birth in a nonpatient sample. Schizophrenia Research 2008, 103:151-155.
31. Kirkpatrick B., Fernandez-Egea E., Garcia-Rizo C., Bernardo M. Differences in glucose tolerance between deficit and nondeficit schizophrenia. Schizophrenia Research 2009, 107:122-127.
32. Laan W., Selten J.P., Grobbee D.E., Smeets H., Kahn R.S., Burger H. Non-steroidal anti-inflammatory drugs and the risk of psychosis. European Neuropsychopharmacology 2007, 17:309-311.
33. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpe S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Research 1998, 32:9-15.
34. Liu Y.L., Liu C.M., Fann C.S., Yang W.C., Chen Y.H., Tseng L.J., Liu S.K., Hsieh M.H., Hwang T.J., Chan H.Y., Chen J.J., Chen W.J., Hwu H.G. Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan. Neuroscience Letters 2010, 468(3):330-333.
35. Lowe G.D. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. Journal of Thrombosis and Haemostasia 2005, 3:1618-1627.
36. Messias E., Bienvenu O.J. Suspiciousness and alcohol use disorders in schizophrenia. Journal of Nervous and Mental Disease 2003, 191:387-390.
37. Messias E., Kirkpatrick B. Summer birth and deficit schizophrenia in the epidemiological catchment area study. Journal of Nervous and Mental Disease 2001, 189:608-612.
38. Messias E., Kirkpatrick B., Bromet E., Ross D., Buchanan R.W., Carpenter W.T., Tek C., Kendler K.S., Walsh D., Dollfus S. Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Archives of General Psychiatry 2004, 61:985-989.
39. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic affects. Biological Psychiatry 2011, 70(7):663-671.
40. Mucci A., Galderisi S., Kirkpatrick B., Bucci P., Volpe U., Merlotti E., Centanaro F., Catapano F., Maj M. Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophrenia Research 2007, 92:252-261.
41. Müller N., Riedel M., Ackenheil M., Schwarz M.J. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World Journal of Biological Psychiatry 2000, 1:173-179.
42. Müller N., Strassnig M., Schwarz M.J., Ulmschneider M., Riedel M. COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opinion on Investigational Drugs 2004, 13:1033-1044.
43. Müller N., Riedel M., Schwarz M.J., Engel R.R. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2005, 255:149-151.
44. Müller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., Möller H.J., Klauss V., Schwarz M.J., Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Research 2010, 121:118-124.
45. Papanicolaou D.A., Vgontzas A.N. Interleukin-6: the endocrine cytokine. Journal of Clinical Endocrinology Metabolism 2000, 85:1331-1333.
46. Schwarz M.J., Müller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Medical Hypotheses 2001, 56:483-486.
47. Singh B., Bera N.K., Nayak C.R., Chaudhuri T.K. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009, 47:1-5.
48. Szuster-Ciesielska A., Slotwinska M., Stachura A., Marmurowska-Michalowska H., Kandefer-Szerszen M. Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers. Archives of Immunolgy and Experimental Therapy (Warsz) 2004, 52:59-67.
49. Tek C., Kirkpatrick B., Buchanan R.W. A five-year followup study of deficit and nondeficit schizophrenia. Schizophrenia Research 2001, 49:253-260.
50. Torrey E.F., Miller J., Rawlings R., Yolken R.H. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophrenia Research 1997, 28:1-38.
51. Wang X., Yao S., Kirkpatrick B., Shi C., Yi J. Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. Psychiatry Research 2008, 158:195-205.